Roche today announced that the first in class Hedgehog pathway inhibitor vismodegib, was named Drug Discovery of the Year by the British Pharmacological Society.
20 December, 2012
The early and simultaneous consideration of potency, selectivity and ADMET (absorption, distribution, metabolism, excretion and toxicity) has become a characteristic feature of modern drug discovery. Today, prediction methods are an integral part of technology platforms for lead finding and optimization. Besides the efficient application of proven prediction methods, the field needs new developments yielding robust, precise models. Protein structure-based approaches in ADMET prediction might be one of those new paths.
19 December, 2012
A new study by NYU School of Medicine researchers suggests that an existing HIV drug called maraviroc could be a potential therapy for Staphylococcus aureus, a notorious and deadly pathogen linked to hundreds of thousands of hospitalizations each year. Their study is published online this week in Nature.
18 December, 2012
A system of `automated design’ for new drugs could help develop the complex therapies needed for many medical conditions while also improving drug safety and efficiency, new research from the University of Dundee has shown.
12 December, 2012
The Istituto Italiano di Tecnologia researchers have been able to capture, by Transmission Electron Microscopy, the direct and background-free image of the DNA Double Helix, paving the way to the direct study of the interaction between DNA and proteins, RNA and other molecules.
12 December, 2012
Biologists at UC San Diego have succeeded in genetically engineering algae to produce a complex and expensive human therapeutic drug used to treat cancer.
12 December, 2012
Alacrita, the transatlantic firm which is changing the face of life science consulting, is delighted to launch its 2012 Life Sciences Seasonal Appeal. Alacrita is offering the unique opportunity for individuals from the life sciences industry to bid for a two-hour, one-to-one lunch with senior executives from the pharmaceutical industry.
10 December, 2012
The latest issue of Drug Discovery Today is packed full of industry focused research articles, new developments in drug discovery, and expert comment and opinion.
10 December, 2012
Sanford-Burnham Medical Research Institute (Sanford-Burnham) has announced that two of the Institute’s research teams have won Space Florida’s International Space Station (ISS) Research Competition. Eight teams were selected from a pool of international applicants to send experiments to space in late 2013. The competition was initiated by Space Florida, the state’s spaceport and aerospace authority, and NanoRacks, LLC. Sanford-Burnham’s research will fly as payloads to the ISS aboard a SpaceX Falcon 9 launch vehicle and research will be conducted on board the U.S. National Lab at the ISS.
03 December, 2012
Pfizer Limited announced today that Xalkori (crizotinib), the first of a new class of therapy for a type of lung cancer is now available in the UK. Crizotinib, an oral treatment, has been granted a conditional licence for patients with previously treated advanced non-small cell lung cancer (NSCLC), whose tumours test positively for a specific protein known as ALK. It is the only approved therapy for this subset of non-small cell lung cancer (NSCLC) patients and signals the most recent advance in personalised therapy in lung cancer.
03 December, 2012